SEC EDGARJUN 262 min read$SN

Barrocas Mark sold $14.5M of SN

Barrocas Mark (Chief Executive Officer) sold 100,000 shares of SharkNinja, Inc. (SN) at $145.00 ($14.50M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Barrocas Mark

Published Jun 26, 2026, 4:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 6, 2026, 6:56 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$SN

Neutral

medium confidence

Mentioned

$SN

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$SNNeutralLow

Why it matters

The newest concrete fact is the disclosed sale size ($14.5M) and execution price ($145/share) on 2026-06-25, filed on 2026-06-26.

Market read

A large CEO sale can create short-term sentiment noise, but the 10b5-1 framing limits inference about near-term fundamentals.

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, contracts, or fundamentals, the signal is likely secondary.

Relevance 6/10Novelty 5/10Timing: filed 2026-06-26, transaction dated 2026-06-25

Background

This is an SEC Form 4 insider transaction by SharkNinja CEO Mark Barrocas, reporting an open-market sale of 100,000 shares.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$SNNeutralMedium confidence

Context

SharkNinja CEO Mark Barrocas filed a Form 4 selling 100,000 shares at $145 for about $14.5M, under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; any move would be more about broader market/insider-sale interpretation than new fundamentals.

Evidence & confidence

Form 4 discloses the transaction size and price, but the article provides no new company-specific operating or guidance information. The presence of a pre-arranged 10b5-1 plan typically reduces interpretive weight.

Market effects

Sector

Insider-sale disclosures can marginally influence sentiment across consumer/household tech names, but no sector-wide signal is provided here.

Regional

No direct regional market linkage beyond US-listed insider activity.

Global

No global catalyst described; impact is company-specific sentiment only.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect diversification or liquidity needs rather than bearish expectations.

Key entities

issuer
SharkNinja, Inc.
US-listed company whose CEO insider sale is disclosed on Form 4.
insider
Mark Barrocas
CEO and director who sold 100,000 shares under a 10b5-1 plan.

Read at source ← All news

OCT 24

$JNJMedAI 8/10

J&J’s Smith & Nephew Deal Collapsed Over One Executive. Here’s What It Means for the DePuy Spin

Johnson & Johnson (JNJ) and Smith & Nephew (SN) ended merger talks over leadership disputes. J&J's orthopaedics unit, valued at up to $22B, may instead be spun off. J&J shares fell 1.42% on the news. The spin is expected in mid-2027, with a pro forma to be released on December 8.

finance.yahoo.com2 min

OCT 23

$SNHighAI 8/10

Smith & Nephew merger talks with J&J orthopaedics unit collapse over CEO role, FT reports

Smith & Nephew's merger talks with Johnson & Johnson's orthopaedics unit collapsed over disagreement on the CEO role, according to the Financial Times. The deal would have valued the unit at up to $22 billion, nearly double Smith & Nephew's market cap. Both companies were aligned on financial terms but disagreed on leadership. Smith & Nephew's former CEO left in 2019 over pay demands.

investing.com2 min

OCT 19

$SNMed

UBS sees attractive risk/reward in three European medtech into Q3 results

UBS identifies Convatec, Smith & Nephew, and Sonova as attractive European medtech stocks ahead of Q3 results, citing revenue and earnings growth expectations. Convatec is expected to report 6% organic growth, Smith & Nephew may undergo a strategic review, and Sonova could raise guidance due to market growth and currency tailwinds. UBS provides price targets for each company.

investing.com2 min

SEP 3

$SNHighAI 8/10

Blowout Guidance Sends SharkNinja Shares Higher

SharkNinja (SN) reported Q2 2026 net sales of $1.77B (up 22.2% YoY) and adjusted net income of $178M (up 29%). The company raised full-year 2026 guidance, targeting up to 17% sales growth and $6.55 adjusted EPS. SN shares have risen 56% YTD, supported by institutional demand and strong fundamentals, including 3-year sales growth of 20% and EPS growth of 63.8%.

yahoo.com2 min

AUG 12

$SNMed

UBS raises SharkNinja stock price target to $219 on product expansion

UBS raised its price target for SharkNinja (NYSE:SN) to $219.10 from $147 and kept a Buy rating, citing Q2 results and faster product launches. The firm pointed to 13 new products year to date versus nine in the first eight months of 2025, plus plans for up to three new subcategories in 2026. SN trades at $187.68 and reported revenue of $1.77B (+22.2%) with adjusted EPS of $0.92.

investing.com4 min

AUG 10

$SNMedAI 8/10

Should You Buy, Sell or Hold SharkNinja Stock Post Q2 Earnings?

SharkNinja (SN) reported Q2 2026 net sales of $1.77B, up 22.2% YoY, and raised its fiscal 2026 outlook. Adjusted EBITDA rose 18.6% to $264.9M and adjusted EPS increased 29.9% to $1.26. Management now expects net sales growth of 16-17% and adjusted EPS of $6.45-$6.55.

tradingview.com6 min